Greenup Street Wealth Management Boosts Gilead Sciences Stake

Investment firm increases holdings in biopharmaceutical company by 19,408 shares in Q4

Apr. 12, 2026 at 11:20am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic banking equipment and machinery, conveying the robust financial infrastructure supporting Gilead Sciences' biopharmaceutical operations.Gilead Sciences' financial strength and institutional backing are reflected in the company's industrial-grade manufacturing capabilities.Foster City Today

Greenup Street Wealth Management LLC, a financial advisory firm, purchased a new stake of 19,408 shares in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to a recent 13F filing with the SEC. The new position was valued at approximately $2.38 million.

Why it matters

Gilead Sciences is a major biopharmaceutical company known for its antiviral therapies, particularly in the areas of HIV and viral hepatitis. The firm's stock performance and institutional investor activity can provide insights into market sentiment around the company's pipeline and commercial prospects.

The details

Greenup Street Wealth Management's new position in Gilead Sciences was part of a broader trend of institutional investors and hedge funds adjusting their holdings in the company during the fourth quarter. Several other firms, including Brighton Jones LLC, Sivia Capital Partners LLC, and Ieq Capital LLC, also made changes to their Gilead Sciences positions over the same period.

  • Greenup Street Wealth Management purchased the 19,408 Gilead Sciences shares in the fourth quarter of 2025.
  • The 13F filing disclosing the new position was submitted on April 12, 2026.

The players

Greenup Street Wealth Management LLC

A financial advisory firm that recently purchased a new stake in Gilead Sciences, Inc.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

Greenup Street Wealth Management's new position in Gilead Sciences reflects ongoing institutional interest in the biopharmaceutical company and its portfolio of antiviral therapies. The activity highlights the continued importance of Gilead Sciences within the broader healthcare and biotech investment landscape.